A phase III study comparing anastrozole, letrozole and exemastane, upfront (for 5 year) or sequentially (for 3 years after 2 years of tamoxifen), as adjuvant treatment of postmenopausal patients with endocrine-responsive breast cancer

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

Ruhstaller, T.
Giobbie-Hurder, A.
Colleoni, M.
Jensen, M.B.
Ejlertsen, B.
de Azambuja, E.
Neven, P.
Láng, I.
Jakobsen, E.H.
Gladieff, L.
Bonnefoi, H.
Harvey, V.J.
Spazzapan, S.
Tondini, C.
Del Mastro, L.
Veyret, C.
Simoncini, E.
Gianni, L.
Rochlitz, C.
Kralidis, E.
Zaman, K.
Jassem, J.
Piccart-Gebhart, M.
Di Leo, A.
Gelber, R.D.
Coates, A.S.
Goldhirsch, A.
Thürlimann, B.
Regan, M.M.

January 2019

Luminal breast cancer has a long natural history, with recurrences continuing beyond 10 years after ...

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

Rasmussen, B.B.
Regan, M.M.
Lykkesfeldt, A.E.
Dell'Orto, P.
Del Curto, B.
Henriksen, K.L.
Mastropasqua, M.G.
Price, K.N.
Mery, E.
Lacroix-Triki, M.
Braye, S.
Altermatt, H.J.
Gelber, R.D.
Castiglione-Gertsch, M.
Goldhirsch, A.
Gusterson, B.A.
Thurlimann, B.
Coates, A.S.
Viale, G.

January 2008

Background The Breast International Group (BIG) 1-98 trial (a randomised double-blind phase III tria...

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptorpositive breast cancer (ANZ0501 LATER) : an open-label randomised, controlled trial

Zdenkowski, N.
Forbes, J. F.
Boyle, F. M.
Kannourakis, G.
Gill, P. G.
Bayliss, E.
Saunders, C.
Della-Fiorentina, Stephen (R18704)
Kling, N.
Campbell, I.
Mann, G. B.
Coates, A. S.
Gebski, V.
Davies, L.
Thornton, R.
Reaby, L.
Cuzick, J.
Green, M.
Australian-New Zealand Breast Cancer Trials Group

January 2016

Background: Despite the effectiveness of adjuvant endocrine therapy in preventing breast cancer recu...

A phase III study comparing anastrozole, letrozole and exemastane, upfront (for 5 year) or sequentially (for 3 years after 2 years of tamoxifen), as adjuvant treatment of postmenopausal patients with endocrine-responsive breast cancer

Di Renzo G

January 2007

Multicenter, open label, six arms factorial phase III randomized study comparing anastrozole, letroz...

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

A. Buzdar
J. Douma
N. Davidson
R. Elledge
M. Morgan
R. Smith
L. Porter
J. Nabholtz
X. Xiang
C. Brady

January 2001

and 2.5 mg every day) and megestrol acetate (40 mg qid) as endocrine therapy in postmenopausal women...

Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial

Goss, Paul E.
Ingle, James N.
Pritchard, Kathleen I.
Ellis, Matthew J.
Sledge, George W.
Budd, G. Thomas
Rabaglio, Manuela
Ansari, Rafat H.
Johnson, David B.
Tozer, Richard
D'Souza, David P.
Chalchal, Haji
Spadafora, Silvana
Stearns, Vered
Perez, Edith A.
Liedke, Pedro E. R.
Lang, Istvan
Elliott, Catherine
Gelmon, Karen A.
Chapman, Judy-Anne W.
Shepherd, Lois E.

April 2013

PURPOSE In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therap...

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

De Placido S.
Gallo C.
De Laurentiis M.
Bisagni G.
Arpino G.
Sarobba M. G.
Riccardi F.
Russo A.
Del Mastro L.
Cogoni A. A.
Cognetti F.
Gori S.
Foglietta J.
Frassoldati A.
Amoroso D.
Laudadio L.
Moscetti L.
Montemurro F.
Verusio C.
Bernardo A.
Lorusso V.
Gravina A.
Moretti G.
Lauria R.
Lai A.
Mocerino C.
Rizzo S.
Nuzzo F.
Carlini P.
Perrone F.
Accurso A.
Agostara B.
Aieta M.
Alabiso O.
Alicicco M. G.
Amadori D.
Amaducci L.
Amiconi G.
Antuzzi G.
Ardine M.
Ardizzoia A.
Aversa C.
Badalamenti G.
Barni S.
Basurto C.
Berardi R.
Bergamasco C.
Bidoli P.
Bighin C.
Biondi E.
Bisagni G.
Boni C.
Borgonovo K.
Botta M.
Bravi S.
Bruzzi P.
Buono G.
Butera A.
Caldara A.
Candeloro G.
Cappelletti C.
Cardalesi C.
Carfora E.
Cariello A.
Carrozza F.
Carteni G.
Caruso M.
Casadei V.
Casanova C.
Castori L.
Cavanna L.
Cavazzini G.
Cazzaniga M.
Chilelli M.
Chiodini P.
Chiorrini S.
Ciardiello F.
Ciccarese M.
Cinieri S.
Clerico M.
Coccaro M.
Comande M.
Corbo C.
Cortino G.
Cusenza S.
Daniele G.
D'arco A. M.
D'auria G.
Dazzi C.
De Angelis C.
de Braud F.
De Feo G.
De Matteis MA.
De Tursi M.
Di Blasio A.
di Lucca G.
Di Lullo L.
Di Rella F.
Di Renzo G.
Di Stefano P.
Di Stefano A.
Diana A.
Donati S.
Fabbri A.
Fabi A.
Faedi M.
Farina G.
Farris A.
Febbraro A.
Fedele P.
Federico P.
Ferrau F.
Ferretti G.
Ferro A.
Floriani I.
Forcignano R.
Forciniti S.
Forestieri V.
Fornari G.
Frisinghelli M.
Fusco V.
Gallizzi G.
Galvano A.
Gambardella A.
Gambi A.
Gebbia V.
Gervasi E.
Ghilardi M.
Giacobino A.
Giardina G.
Giotta F.
Giraudi S.
Giuliano M.
Grassadonia A.
Grasso D.
Grosso F.
Guizzaro L.
Incoronato P.
Incorvaia L.
Iodice G.
La Verde N.
Labonia V.
Landi G.
Latorre A.
Leonardi V.
Levaggi A.
Limite G.
Lina Bascialla L.
Livi L.
Maiello E.
Mandelli D.
Marcon I.
Menon D.
Montedoro M.
Moraca L.
Moretti A.
Morritti M. G.
Morselli P.
Mura A.
Mura S.
Musacchio M.
Muzio A.
Natale D.
Natoli C.
Nigro C.
Nistico C.
Nuzzo A.
Orditura M.
Orlando L.
Pacilio C.
Palumbo G.
Palumbo R.
Pasini F.
Paterno E.
Pazzola A.
Pelliccioni S.
Pensabene M.
Perroni D.
Pesenti Gritti A.
Petrelli F.
Piccirillo M. C.
Pinotti G.
Pogliani C.
Poli D.
Prader S.
Recchia F.
Rizzi D.
Romano C.
Rossello R.
Rossini C.
Salvucci G.
Sanna V.
Santini A.
Saracchini S.
Savastano C.
Scambia G.
Schettini F.
Schiavone P.
Schirone A.
Seles E.
Signoriello S.
Signoriello G.
Silva R. R.
Silvestri A.
Simeon V.
Spagnoletti I.
Tamberi S.
Teragni C.
Thalmann V.
Thomas R.
Thomas G.
Tienghi A.
Tinari N.
Tinessa V.
Tomei F.
Tonini G.
Torri V.
Traficante D.
Tudini M.
Turazza M.
Vignoli R.
Vitale M. G.
Zacchia A.
Zagarese P.
Zanni A.
Zavallone L.
Zavettieri M.
Zoboli A.

January 2018

Background Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with...

Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer

Iaffaioli, R.
Formato, R.
Tortoriello, A.
DEL PRETE, S.
Caraglia, M.
Pappagallo, G.
Pisano, A.
Gebbia, V.
Fanelli, F.
Ianniello, G.
Cigolari, S.
Pizza, C.
Marano, O.
Pezzella, G.
Pedicini, T.
Febbraro, A.
Incoronato, P.
Manzione, L.
Ferrari, E.
Marzano, N.
Quattrin, S.
Pisconti, S.
Nasti, G.
Giotta, G.
Colucci, G.

January 2005

Hormonal therapy is the preferred systemic treatment for recurrent or metastatic, post-menopausal ho...

Increasing protection after tamoxifen: insights from the extended adjuvant aromatase inhibitor trials.

Rose, Carsten

January 2008

For disease-free postmenopausal women with hormone-responsive breast cancer, a risk for relapse rema...

A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer

Rose, Carsten

January 2003

Randomized clinical trials have established the role of third-generation aromatase inhibitors (AIs) ...

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.

Paridaens, R.
Dirix, L.Y.
Beex, L.V.A.M.
Nooij, M.
Cameron, D.
Cufer, T.
Piccart, M.
Bogaerts, J.
Therasse, P.

January 2008

PURPOSE: This phase III randomized open-label clinical trial was designed to evaluate the efficacy a...

Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy

Jerusalem, Guy
Farah, Subrina
Courtois, A.
Chirgwin, Jacquie
Aebi, Stefan
Karlsson, Per
Neven, Patrick
Hitre, Erika
Graas, Marie-Pascale
Simoncini, Edda
Abdi, Ehtesham
Kamby, Claus
Thompson, Alastair
Loibl, Sibylle
Gavila, Joaquín
Kuroi, Katsumasa
Marth, Christian
Müller, Berit Maria B.
O'Reilly, Séamus
Gombos, Andrea
Ruhstaller, Thomas
Burstein, Harold H.J.
Rabaglio, Manuela
Ruepp, Barbara
Ribi, Karin
Viale, Giuseppe
Gelber, Richard
Coates, Alan A.S.
Loi, Sherene
Goldhirsch, Aron
Regan, Meredith
Colleoni, Marco Angelo

October 2021

Background: Late recurrences in postmenopausal women with hormone receptor-positive breast cancers r...

Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.

JERUSALEM, Guy
Farah, S
Courtois, Audrey
Chirgwin, J
Aebi, S
Karlsson, P
Neven, P
Hitre, E
Graas, M P
Simoncini, E
Abdi, E
Kamby, C
Thompson, A
Loibl, S
Gavilá, J
Kuroi, K
Marth, C
Müller, B
O'Reilly, S
Gombos, A
Ruhstaller, T
Burstein, H J
Rabaglio, M
Ruepp, B
Ribi, K
Viale, G
Gelber, R D
Coates, A S
Loi, S
Goldhirsch, A
Regan, M M
Colleoni, M
SOLE Investigators

August 2021

peer reviewed[en] BACKGROUND: Late recurrences in postmenopausal women with hormone receptor-positiv...

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

Paridaens, Robert
Dirix, LY
Beex, LV
Nooij, M
Cameron, DA
Cufer, T
Piccart, MJ
Bogaerts, J
Therasse, P

October 2008

PURPOSE: This phase III randomized open-label clinical trial was designed to evaluate the efficacy a...

Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial

Del Mastro L.
Mansutti M.
Bisagni G.
Ponzone R.
Durando A.
Amaducci L.
Campadelli E.
Cognetti F.
Frassoldati A.
Michelotti A.
Mura S.
Urracci Y.
Sanna G.
Gori S.
De Placido S.
Garrone O.
Fabi A.
Barone C.
Tamberi S.
Bighin C.
Puglisi F.
Moretti G.
Arpino G.
Ballestrero A.
Poggio F.
Lambertini M.
Montemurro F.
Bruzzi P.

January 2021

Background: The benefit of extending aromatase inhibitor therapy beyond 5 years in the context of pr...

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

Ruhstaller, T.
Giobbie-Hurder, A.
Colleoni, M.
Jensen, M.B.
Ejlertsen, B.
de Azambuja, E.
Neven, P.
Láng, I.
Jakobsen, E.H.
Gladieff, L.
Bonnefoi, H.
Harvey, V.J.
Spazzapan, S.
Tondini, C.
Del Mastro, L.
Veyret, C.
Simoncini, E.
Gianni, L.
Rochlitz, C.
Kralidis, E.
Zaman, K.
Jassem, J.
Piccart-Gebhart, M.
Di Leo, A.
Gelber, R.D.
Coates, A.S.
Goldhirsch, A.
Thürlimann, B.
Regan, M.M.

January 2019

Luminal breast cancer has a long natural history, with recurrences continuing beyond 10 years after ...

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

Rasmussen, B.B.
Regan, M.M.
Lykkesfeldt, A.E.
Dell'Orto, P.
Del Curto, B.
Henriksen, K.L.
Mastropasqua, M.G.
Price, K.N.
Mery, E.
Lacroix-Triki, M.
Braye, S.
Altermatt, H.J.
Gelber, R.D.
Castiglione-Gertsch, M.
Goldhirsch, A.
Gusterson, B.A.
Thurlimann, B.
Coates, A.S.
Viale, G.

January 2008

Background The Breast International Group (BIG) 1-98 trial (a randomised double-blind phase III tria...

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptorpositive breast cancer (ANZ0501 LATER) : an open-label randomised, controlled trial

Zdenkowski, N.
Forbes, J. F.
Boyle, F. M.
Kannourakis, G.
Gill, P. G.
Bayliss, E.
Saunders, C.
Della-Fiorentina, Stephen (R18704)
Kling, N.
Campbell, I.
Mann, G. B.
Coates, A. S.
Gebski, V.
Davies, L.
Thornton, R.
Reaby, L.
Cuzick, J.
Green, M.
Australian-New Zealand Breast Cancer Trials Group

January 2016

Background: Despite the effectiveness of adjuvant endocrine therapy in preventing breast cancer recu...

A phase III study comparing anastrozole, letrozole and exemastane, upfront (for 5 year) or sequentially (for 3 years after 2 years of tamoxifen), as adjuvant treatment of postmenopausal patients with endocrine-responsive breast cancer

Di Renzo G

January 2007

Multicenter, open label, six arms factorial phase III randomized study comparing anastrozole, letroz...

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

A. Buzdar
J. Douma
N. Davidson
R. Elledge
M. Morgan
R. Smith
L. Porter
J. Nabholtz
X. Xiang
C. Brady

January 2001

and 2.5 mg every day) and megestrol acetate (40 mg qid) as endocrine therapy in postmenopausal women...

Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial

Goss, Paul E.
Ingle, James N.
Pritchard, Kathleen I.
Ellis, Matthew J.
Sledge, George W.
Budd, G. Thomas
Rabaglio, Manuela
Ansari, Rafat H.
Johnson, David B.
Tozer, Richard
D'Souza, David P.
Chalchal, Haji
Spadafora, Silvana
Stearns, Vered
Perez, Edith A.
Liedke, Pedro E. R.
Lang, Istvan
Elliott, Catherine
Gelmon, Karen A.
Chapman, Judy-Anne W.
Shepherd, Lois E.

April 2013

PURPOSE In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therap...

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

De Placido S.
Gallo C.
De Laurentiis M.
Bisagni G.
Arpino G.
Sarobba M. G.
Riccardi F.
Russo A.
Del Mastro L.
Cogoni A. A.
Cognetti F.
Gori S.
Foglietta J.
Frassoldati A.
Amoroso D.
Laudadio L.
Moscetti L.
Montemurro F.
Verusio C.
Bernardo A.
Lorusso V.
Gravina A.
Moretti G.
Lauria R.
Lai A.
Mocerino C.
Rizzo S.
Nuzzo F.
Carlini P.
Perrone F.
Accurso A.
Agostara B.
Aieta M.
Alabiso O.
Alicicco M. G.
Amadori D.
Amaducci L.
Amiconi G.
Antuzzi G.
Ardine M.
Ardizzoia A.
Aversa C.
Badalamenti G.
Barni S.
Basurto C.
Berardi R.
Bergamasco C.
Bidoli P.
Bighin C.
Biondi E.
Bisagni G.
Boni C.
Borgonovo K.
Botta M.
Bravi S.
Bruzzi P.
Buono G.
Butera A.
Caldara A.
Candeloro G.
Cappelletti C.
Cardalesi C.
Carfora E.
Cariello A.
Carrozza F.
Carteni G.
Caruso M.
Casadei V.
Casanova C.
Castori L.
Cavanna L.
Cavazzini G.
Cazzaniga M.
Chilelli M.
Chiodini P.
Chiorrini S.
Ciardiello F.
Ciccarese M.
Cinieri S.
Clerico M.
Coccaro M.
Comande M.
Corbo C.
Cortino G.
Cusenza S.
Daniele G.
D'arco A. M.
D'auria G.
Dazzi C.
De Angelis C.
de Braud F.
De Feo G.
De Matteis MA.
De Tursi M.
Di Blasio A.
di Lucca G.
Di Lullo L.
Di Rella F.
Di Renzo G.
Di Stefano P.
Di Stefano A.
Diana A.
Donati S.
Fabbri A.
Fabi A.
Faedi M.
Farina G.
Farris A.
Febbraro A.
Fedele P.
Federico P.
Ferrau F.
Ferretti G.
Ferro A.
Floriani I.
Forcignano R.
Forciniti S.
Forestieri V.
Fornari G.
Frisinghelli M.
Fusco V.
Gallizzi G.
Galvano A.
Gambardella A.
Gambi A.
Gebbia V.
Gervasi E.
Ghilardi M.
Giacobino A.
Giardina G.
Giotta F.
Giraudi S.
Giuliano M.
Grassadonia A.
Grasso D.
Grosso F.
Guizzaro L.
Incoronato P.
Incorvaia L.
Iodice G.
La Verde N.
Labonia V.
Landi G.
Latorre A.
Leonardi V.
Levaggi A.
Limite G.
Lina Bascialla L.
Livi L.
Maiello E.
Mandelli D.
Marcon I.
Menon D.
Montedoro M.
Moraca L.
Moretti A.
Morritti M. G.
Morselli P.
Mura A.
Mura S.
Musacchio M.
Muzio A.
Natale D.
Natoli C.
Nigro C.
Nistico C.
Nuzzo A.
Orditura M.
Orlando L.
Pacilio C.
Palumbo G.
Palumbo R.
Pasini F.
Paterno E.
Pazzola A.
Pelliccioni S.
Pensabene M.
Perroni D.
Pesenti Gritti A.
Petrelli F.
Piccirillo M. C.
Pinotti G.
Pogliani C.
Poli D.
Prader S.
Recchia F.
Rizzi D.
Romano C.
Rossello R.
Rossini C.
Salvucci G.
Sanna V.
Santini A.
Saracchini S.
Savastano C.
Scambia G.
Schettini F.
Schiavone P.
Schirone A.
Seles E.
Signoriello S.
Signoriello G.
Silva R. R.
Silvestri A.
Simeon V.
Spagnoletti I.
Tamberi S.
Teragni C.
Thalmann V.
Thomas R.
Thomas G.
Tienghi A.
Tinari N.
Tinessa V.
Tomei F.
Tonini G.
Torri V.
Traficante D.
Tudini M.
Turazza M.
Vignoli R.
Vitale M. G.
Zacchia A.
Zagarese P.
Zanni A.
Zavallone L.
Zavettieri M.
Zoboli A.

January 2018

Background Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with...

Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer

Iaffaioli, R.
Formato, R.
Tortoriello, A.
DEL PRETE, S.
Caraglia, M.
Pappagallo, G.
Pisano, A.
Gebbia, V.
Fanelli, F.
Ianniello, G.
Cigolari, S.
Pizza, C.
Marano, O.
Pezzella, G.
Pedicini, T.
Febbraro, A.
Incoronato, P.
Manzione, L.
Ferrari, E.
Marzano, N.
Quattrin, S.
Pisconti, S.
Nasti, G.
Giotta, G.
Colucci, G.

January 2005

Hormonal therapy is the preferred systemic treatment for recurrent or metastatic, post-menopausal ho...

Increasing protection after tamoxifen: insights from the extended adjuvant aromatase inhibitor trials.

Rose, Carsten

January 2008

For disease-free postmenopausal women with hormone-responsive breast cancer, a risk for relapse rema...

A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer

Rose, Carsten

January 2003

Randomized clinical trials have established the role of third-generation aromatase inhibitors (AIs) ...

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.

Paridaens, R.
Dirix, L.Y.
Beex, L.V.A.M.
Nooij, M.
Cameron, D.
Cufer, T.
Piccart, M.
Bogaerts, J.
Therasse, P.

January 2008

PURPOSE: This phase III randomized open-label clinical trial was designed to evaluate the efficacy a...

Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy

Jerusalem, Guy
Farah, Subrina
Courtois, A.
Chirgwin, Jacquie
Aebi, Stefan
Karlsson, Per
Neven, Patrick
Hitre, Erika
Graas, Marie-Pascale
Simoncini, Edda
Abdi, Ehtesham
Kamby, Claus
Thompson, Alastair
Loibl, Sibylle
Gavila, Joaquín
Kuroi, Katsumasa
Marth, Christian
Müller, Berit Maria B.
O'Reilly, Séamus
Gombos, Andrea
Ruhstaller, Thomas
Burstein, Harold H.J.
Rabaglio, Manuela
Ruepp, Barbara
Ribi, Karin
Viale, Giuseppe
Gelber, Richard
Coates, Alan A.S.
Loi, Sherene
Goldhirsch, Aron
Regan, Meredith
Colleoni, Marco Angelo

October 2021

Background: Late recurrences in postmenopausal women with hormone receptor-positive breast cancers r...

Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.

JERUSALEM, Guy
Farah, S
Courtois, Audrey
Chirgwin, J
Aebi, S
Karlsson, P
Neven, P
Hitre, E
Graas, M P
Simoncini, E
Abdi, E
Kamby, C
Thompson, A
Loibl, S
Gavilá, J
Kuroi, K
Marth, C
Müller, B
O'Reilly, S
Gombos, A
Ruhstaller, T
Burstein, H J
Rabaglio, M
Ruepp, B
Ribi, K
Viale, G
Gelber, R D
Coates, A S
Loi, S
Goldhirsch, A
Regan, M M
Colleoni, M
SOLE Investigators

August 2021

peer reviewed[en] BACKGROUND: Late recurrences in postmenopausal women with hormone receptor-positiv...

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

Paridaens, Robert
Dirix, LY
Beex, LV
Nooij, M
Cameron, DA
Cufer, T
Piccart, MJ
Bogaerts, J
Therasse, P

October 2008

PURPOSE: This phase III randomized open-label clinical trial was designed to evaluate the efficacy a...

Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial

Del Mastro L.
Mansutti M.
Bisagni G.
Ponzone R.
Durando A.
Amaducci L.
Campadelli E.
Cognetti F.
Frassoldati A.
Michelotti A.
Mura S.
Urracci Y.
Sanna G.
Gori S.
De Placido S.
Garrone O.
Fabi A.
Barone C.
Tamberi S.
Bighin C.
Puglisi F.
Moretti G.
Arpino G.
Ballestrero A.
Poggio F.
Lambertini M.
Montemurro F.
Bruzzi P.

January 2021

Background: The benefit of extending aromatase inhibitor therapy beyond 5 years in the context of pr...

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

Ruhstaller, T.
Giobbie-Hurder, A.
Colleoni, M.
Jensen, M.B.
Ejlertsen, B.
de Azambuja, E.
Neven, P.
Láng, I.
Jakobsen, E.H.
Gladieff, L.
Bonnefoi, H.
Harvey, V.J.
Spazzapan, S.
Tondini, C.
Del Mastro, L.
Veyret, C.
Simoncini, E.
Gianni, L.
Rochlitz, C.
Kralidis, E.
Zaman, K.
Jassem, J.
Piccart-Gebhart, M.
Di Leo, A.
Gelber, R.D.
Coates, A.S.
Goldhirsch, A.
Thürlimann, B.
Regan, M.M.

January 2019

Luminal breast cancer has a long natural history, with recurrences continuing beyond 10 years after ...

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

Rasmussen, B.B.
Regan, M.M.
Lykkesfeldt, A.E.
Dell'Orto, P.
Del Curto, B.
Henriksen, K.L.
Mastropasqua, M.G.
Price, K.N.
Mery, E.
Lacroix-Triki, M.
Braye, S.
Altermatt, H.J.
Gelber, R.D.
Castiglione-Gertsch, M.
Goldhirsch, A.
Gusterson, B.A.
Thurlimann, B.
Coates, A.S.
Viale, G.

January 2008

Background The Breast International Group (BIG) 1-98 trial (a randomised double-blind phase III tria...

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptorpositive breast cancer (ANZ0501 LATER) : an open-label randomised, controlled trial

Zdenkowski, N.
Forbes, J. F.
Boyle, F. M.
Kannourakis, G.
Gill, P. G.
Bayliss, E.
Saunders, C.
Della-Fiorentina, Stephen (R18704)
Kling, N.
Campbell, I.
Mann, G. B.
Coates, A. S.
Gebski, V.
Davies, L.
Thornton, R.
Reaby, L.
Cuzick, J.
Green, M.
Australian-New Zealand Breast Cancer Trials Group

January 2016

Background: Despite the effectiveness of adjuvant endocrine therapy in preventing breast cancer recu...

A phase III study comparing anastrozole, letrozole and exemastane, upfront (for 5 year) or sequentially (for 3 years after 2 years of tamoxifen), as adjuvant treatment of postmenopausal patients with endocrine-responsive breast cancer

Abstract

Extracted data

A phase III study comparing anastrozole, letrozole and exemastane, upfront (for 5 year) or sequentially (for 3 years after 2 years of tamoxifen), as adjuvant treatment of postmenopausal patients with endocrine-responsive breast cancer

Abstract

Extracted data

Related items

Related items